We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Orthocell Limited is a biotechnology business based in Australia. Orthocell shares (OCC) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Orthocell has a trailing 12-month revenue of around $1 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $0.32 - $0.655 |
|---|---|
| 50-day moving average | $0.4924 |
| 200-day moving average | $0.5253 |
| Target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.048 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.525
| 1 week (2021-10-07) | 5.00% |
|---|---|
| 1 month (2021-09-17) | 6.06% |
| 3 months (2021-07-17) | -4.55% |
| 6 months (2021-04-16) | -1.87% |
| 1 year (2020-10-16) | 40.00% |
|---|---|
| 2 years (2019-10-17) | 12.90% |
| 3 years (2018-10-17) | 118.75% |
| 5 years (2016-10-17) | 25.00% |
| Revenue TTM | $1 million |
|---|---|
| Gross profit TTM | $392,317 |
| Return on assets TTM | -34.21% |
| Return on equity TTM | -47.84% |
| Profit margin | 0% |
| Book value | 0.089 |
| Market capitalisation | $100.6 million |
TTM: trailing 12 months
We're not expecting Orthocell to pay a dividend over the next 12 months.
Over the last 12 months, Orthocell 's shares have ranged in value from as little as $0.32 up to $0.655. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Orthocell 's is 0.0388. This would suggest that Orthocell 's shares are less volatile than average (for this exchange).
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and internationally. The company's principal products include CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation for the treatment of symptomatic defects of the articulating cartilage of the joints, primarily in the knee and ankle. In addition, the company develops Striate+ for use in bone and soft tissue repair; SMRT Graft for use in to augment repair of rotator cuff tendinopathy and tear; and Remplir, a nerve wrap. Orthocell Limited was incorporated in 2006 and is based in Murdoch, Australia.
Shares in the trans-Tasman dairy company are down 55% over the last 12 months.
Shares in the Brisbane-based lender have risen nearly 60% in the last 12 months.
Everything we know about the Tissue Repair IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Illuvium (ILV) token as well as a list of exchanges you can trade it on.
Westpac shares are up 43% over the past 12 months.
Airports, travel agents and pubs are set to soar post lockdown, but should share investors look beyond immediate short-term wins?
Shares in the insurer are up just 10% in the last 12 months.
Everything we know about the Nimy Resources IPO, plus information on how to buy in.
The payment services company’s shares are up 16% in the last year.
